[Establishment and characterization of a new human myeloid leukemia cell line SH-2]. 2009

Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, China.

OBJECTIVE To establish and characterize a novel human myeloid leukemia cell line SH-2. METHODS Bone marrow mononuclear cells (BMMNC) isolated from a AML-M2 patient, who failed to obtain complete remission after chemotherapy and allogenic bone marrow transplantation were passed in a long term IMDM culture medium supplemented with 20% fetal calf serum. Stromal cells were retained and rh-IL-3 was added in the culture system. A new human myeloid leukemia cell line SH-2 was successfully established with a cytogenetic characteristics of a loss of Y chromosome (-Y), a derivative chromosome 16 resulting from unbalanced translocation between chromosome 16 and 17, monosome 17, trisomy 19 and p53 alteration. Various methods were employed to characterize SH-2 cell line. RESULTS SH-2 cells has been maintained without cytokine and stromal cells for more than 3 years without EB virus and mycoplasma contamination. SH-2 cells had the basically same morphological, immunophenotypic and cytogenetic features as the patient's leukemia cells did, such as myeloid morphology, an immunophenotype of CD13+, CD33+, CD56+, CD16/56+ and a hypodiploid karyotype of 45, X, -Y, der(16)t(16;17)(q24;ql2), -17, +19, which were gradually decreased and replaced by the near-tetraploid cells with a karyotype of 73-102(80), XX, -Y, -Y, del (q131)x2, der(16)t(16;17)(q24;q12)x2, -17, -17, +19, +19. FISH and multiple FISH delineated all the abnormalities and revealed a loss of one p53 allele due to monosomy 17. DNA direct sequencing detected a point mutation of CAG to CAT at codon 576 of exon 5 in another p53 allele. RT-PCR showed that SH-2 cells expressed apoptosis-related genes (bcl-2, Fas, GST-pi and p2) rather than MDR-related genes. Short tandem repeat PCR provided powerful evidence for the derivation of SH-2 cell line from the patient's leukemia cells. SH-2 cells had certain colony formation and tumorigenic capacities in nude and SCID mice. CONCLUSIONS SH-2 is a new myeloid leukemia cell line with a unique biology background, and will provide a useful tool for leukemia research.

UI MeSH Term Description Entries
D008297 Male Males
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016130 Immunophenotyping Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry. Lymphocyte Immunophenotyping,Lymphocyte Subtyping,Immunologic Subtyping,Immunologic Subtypings,Lymphocyte Phenotyping,Subtyping, Immunologic,Subtypings, Immunologic,Immunophenotyping, Lymphocyte,Immunophenotypings,Immunophenotypings, Lymphocyte,Lymphocyte Immunophenotypings,Lymphocyte Phenotypings,Lymphocyte Subtypings,Phenotyping, Lymphocyte,Phenotypings, Lymphocyte,Subtyping, Lymphocyte,Subtypings, Lymphocyte
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018929 Cell Culture Techniques Methods for maintaining or growing CELLS in vitro. Cell Culture,Cell Culture Technique,Cell Cultures,Culture Technique, Cell,Culture Techniques, Cell

Related Publications

Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
October 2009, Leukemia research,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
December 1985, Blood,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
November 1997, Leukemia,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
July 1991, Blood,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
May 1996, The Journal of veterinary medical science,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
August 1982, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
May 1997, Leukemia,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
May 1985, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
September 2014, Leukemia research,
Hui-Ying Qiu, and Yong-Quan Xue, and Jun Zhang, and Hai-Ping Dai, and Jin-Lan Pan, and Ya-Fang Wu, and Su-Ning Chen, and Yong Wang, and Juan Shen, and Ai-Ning Sun, and De-Pei Wu
May 1984, Journal of the National Cancer Institute,
Copied contents to your clipboard!